Truist Securities, TD Cowen, Citigroup Inc. ( C) and Canaccord Genuity all also rate BSX "buy," while JPMorgan Chase & Co. ( ...
BofA Securities maintained a Buy rating on Eli Lilly stock (NYSE:LLY), with a price target set at $997.00. With a market capitalization of $706 billion and impressive revenue growth of 27.4% over the ...
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...
Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side effects.
Wedge Capital Management L L P NC decreased its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 26.0% ...
China has become a key piece of Foresite Capital’s investment and company formation strategy. During the J.P. Morgan Healthcare Conference, Managing Director Michael Rome shared his thoughts on why ...
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...
All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...
We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...